No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305
| Autor: | Ying Q. Chen, Shashi N Kapadia, Kenneth H. Mayer, Bruce R. Schackman, Adriana Andrade, Wairimu Chege, K. Rivet Amico, Marybeth McCauley, Raphael J. Landovitz, Timothy J. Wilkin, Chunyuan Wu, Roy M. Gulick |
|---|---|
| Přispěvatelé: | Li, Xiang |
| Rok vydání: | 2018 |
| Předmět: |
RNA viruses
Male HIV Infections Pathology and Laboratory Medicine 01 natural sciences law.invention Maraviroc Pre-exposure prophylaxis chemistry.chemical_compound Mathematical and Statistical Techniques 0302 clinical medicine Immunodeficiency Viruses Randomized controlled trial law Transgender Medicine and Health Sciences Ethnicities Emtricitabine Public and Occupational Health 030212 general & internal medicine Hispanic People education.field_of_study Multidisciplinary Statistics Middle Aged Marijuana 3. Good health Infectious Diseases Medical Microbiology Behavioral Pharmacology Viral Pathogens Viruses Physical Sciences Medicine HIV/AIDS Regression Analysis Female Pathogens Research Article medicine.drug Adult Adolescent General Science & Technology Science Clinical Trials and Supportive Activities HIV prevention Population Sexual and Gender Minorities (SGM/LGBT*) Linear Regression Analysis Research and Analysis Methods Microbiology 03 medical and health sciences Clinical Research Recreational Drug Use Behavioral and Social Science Retroviruses medicine Humans Statistical Methods 0101 mathematics Tenofovir education Microbial Pathogens Cannabis Aged Pharmacology Prophylaxis business.industry Prevention Lentivirus 010102 general mathematics Organisms Biology and Life Sciences HIV United States Health Care Clinical trial Regimen Good Health and Well Being chemistry People and Places HIV-1 Quality of Life Women's Health Pre-Exposure Prophylaxis Population Groupings Preventive Medicine business Mathematics Demography |
| Zdroj: | PloS one, vol 13, iss 12 PLoS ONE PLoS ONE, Vol 13, Iss 12, p e0206577 (2018) |
| ISSN: | 1932-6203 0150-5114 |
| DOI: | 10.1371/journal.pone.0206577 |
| Popis: | Author(s): Kapadia, Shashi N; Wu, Chunyuan; Mayer, Kenneth H; Wilkin, Timothy J; Amico, K Rivet; Landovitz, Raphael J; Andrade, Adriana; Chen, Ying Q; Chege, Wairimu; McCauley, Marybeth; Gulick, Roy M; Schackman, Bruce R | Abstract: IntroductionTenofovir (TDF)-containing PrEP is effective for HIV prevention, but its effect on health-related quality of life (QOL) is unknown. Using data from HPTN 069/ACTG A5305, a randomized study of potential PrEP regimens comparing maraviroc alone, or together with TDF or emtricitabine (FTC), to TDF + FTC (control), we evaluated the impact of these regimens on QOL in at-risk HIV-uninfected U.S. women and men.MethodsQOL was measured at baseline (before starting medications) and every 8 weeks through week 48 using the EQ-5D-3L. Responses were converted to a scale from 0.0 (death) to 1.0 (perfect health), using published valuation weights. Mean scores were compared between groups at each time point using nonparametric testing. Multivariable linear regression was used to adjust for potential confounders.ResultsWe analyzed 186 women (median age 35 years, 65% black, 17% Hispanic) and 405 men (median age 30 years, 28% black, 22% Hispanic), including 9 transgender participants analyzed based on sex-at-birth. Mean baseline QOL was 0.91 for women and 0.95 for men. There were minimal changes in mean QOL over time for any regimen (women: p = 0.29; men: p = 0.14). There were no significant differences between participants who continued the regimen compared to participants who discontinued early (women: p = 0.61; men: p = 0.1). Mean QOL did not differ significantly by regimen at any time point, both unadjusted and after adjustment for age, race/ethnicity, adherence, and use of alcohol, marijuana, opiates, and other substances.ConclusionsQOL in at-risk individuals starting candidate PrEP regimens in a clinical trial is similar to the general population and maintained over time. This finding did not vary among regimens or when adjusted for demographics, adherence, and substance use. Our findings are the first to show that starting a candidate PrEP regimen in at-risk HIV-uninfected U.S. women and men was not associated with significant changes in QOL.Trial registrationClinicaltrials.gov NCT01505114. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|